HIV patients' quality of life after long-acting injection
Part of Immune system & allergy, Infections clinical trials.
This study looks at how people living with HIV feel (quality of life) and how well their virus is controlled after they finish a long-acting injectable treatment with cabotegravir and rilpivirine. It's a follow-up to see if this easier treatment helps people stay healthy and feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with HIV.
- You must have already completed a long-acting injectable treatment with cabotegravir and rilpivirine.
- You must agree to fill out a questionnaire about your health and well-being.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how people living with HIV feel after switching to a two-shot injection (Cabotegravir and Rilpivirine) given every two months. It collects your feedback on quality of life and symptoms to see how the new treatment works in real life.
This study looks at switching people with HIV from daily or regular oral medicine to long-acting injections (cabotegravir plus rilpivirine). It may help those who are well-controlled on current therapy who prefer injections and can safely take this combination.
This trial is studying a two-drug combination (cabotegravir and lenacapavir) given as long-acting shots for people with HIV. If you are already taking or about to start this combination, your doctor may invite you to join so researchers can track how well it works over time.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
Hear when a new AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.